Olema Pharmaceuticals (OLMA) News Today → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free OLMA Stock Alerts $9.32 -0.52 (-5.28%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLifesci Capital Weighs in on Olema Pharmaceuticals, Inc.'s Q3 2024 Earnings (NASDAQ:OLMA)americanbankingnews.com - May 11 at 4:11 AMOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of "Buy" by Brokeragesamericanbankingnews.com - May 11 at 1:16 AMOlema Pharmaceuticals, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.52) Per Share (NASDAQ:OLMA)marketbeat.com - May 10 at 8:21 AMBuy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial Positionmarkets.businessinsider.com - May 10 at 12:53 AMBuy Rating on Olema Pharmaceuticals: Financial Stability and Promising Drug Development Fuel Positive Outlookmarkets.businessinsider.com - May 9 at 7:52 PMOlema Pharmaceuticals (NASDAQ:OLMA) PT Raised to $28.00 at HC Wainwrightmarketbeat.com - May 9 at 5:39 PMCyrus Harmon Sells 5,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stockamericanbankingnews.com - May 9 at 6:42 AMBuy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis Collaborationmarkets.businessinsider.com - May 9 at 3:58 AMOLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024investorplace.com - May 8 at 11:03 PMOlema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Updateglobenewswire.com - May 8 at 4:02 PMOlema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congressglobenewswire.com - May 8 at 7:02 AMOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 5,000 Sharesinsidertrades.com - May 8 at 6:32 AMCyrus Harmon Sells 15,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stockamericanbankingnews.com - May 4 at 5:30 AMOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $142,650.00 in Stockinsidertrades.com - May 3 at 7:30 AMOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 15,000 Sharesmarketbeat.com - May 2 at 7:32 PMOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - May 2 at 4:37 PMOlema Oncology to Participate in Upcoming Investor Conferences in Mayglobenewswire.com - May 1 at 7:02 AMOlema Pharmaceuticals, Inc. (OLMA)finance.yahoo.com - April 21 at 12:53 AMOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 6.2%marketbeat.com - April 18 at 4:33 PMBuy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edgemarkets.businessinsider.com - April 12 at 9:12 PMHow Olema Oncology moved from layoffs to pivotal cancer drug studiesbizjournals.com - April 10 at 4:18 PMOlema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conferenceglobenewswire.com - April 8 at 4:30 PMOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 2 at 4:29 PMOlema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.89marketbeat.com - April 2 at 10:48 AMOlema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at The Goldman Sachs Groupmarketbeat.com - April 2 at 8:23 AMOlema Pharmaceuticals (NASDAQ:OLMA) Shares Down 5.4% After Insider Sellingmarketbeat.com - April 1 at 11:34 AMOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $219,400.00 in Stockinsidertrades.com - March 30 at 7:35 AMInsider Selling: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells 20,000 Shares of Stockmarketbeat.com - March 29 at 6:40 PMPalazestrant's Journey: Olema Pharmaceuticals' Long Oncology Pathseekingalpha.com - March 28 at 5:59 PMOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 6.9%marketbeat.com - March 19 at 4:53 PMOLMA Jul 2024 12.500 callfinance.yahoo.com - March 16 at 3:49 PMOLMA Apr 2024 22.500 callfinance.yahoo.com - March 16 at 10:49 AMOLMA Oct 2024 25.000 callca.finance.yahoo.com - March 15 at 11:42 PMOLMA Oct 2024 10.000 putca.finance.yahoo.com - March 15 at 11:42 PMOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Down 21.2% in Februarymarketbeat.com - March 14 at 12:47 PMFY2024 EPS Estimates for Olema Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:OLMA)marketbeat.com - March 14 at 6:57 AMOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 11.9%marketbeat.com - March 13 at 1:51 PM3 Best Stocks to Buy Now, 3/13/2024, According to Top Analystsmsn.com - March 13 at 1:08 PMPolar Capital Holdings Plc Takes $9.26 Million Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)marketbeat.com - March 13 at 7:53 AMHC Wainwright Comments on Olema Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:OLMA)marketbeat.com - March 13 at 6:33 AMBuy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunitymarkets.businessinsider.com - March 12 at 9:54 PMBuy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatmentmarkets.businessinsider.com - March 12 at 4:54 PMOlema Pharmaceuticals (NASDAQ:OLMA) Shares Down 8% marketbeat.com - March 12 at 1:24 PMStrong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals’ Palazestrantmarkets.businessinsider.com - March 12 at 6:53 AMOlema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 11 at 4:03 PMAdage Capital Partners GP L.L.C. Has $4.80 Million Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)marketbeat.com - March 11 at 6:42 AMBuy Rating for Olema Pharmaceuticals’ Palazestrant Based on Dual Action Efficacy and Strategic Compatibility in ER+ Breast Cancer Treatmentmarkets.businessinsider.com - March 6 at 7:42 PMOlema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitorsfinance.yahoo.com - March 6 at 7:42 PMOlema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitorsglobenewswire.com - March 6 at 7:03 AMOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 7% After Insider Sellingmarketbeat.com - March 5 at 2:27 PM Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Collapse of the Petrodollar (Ad)The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason. In answer to this issue, we have released a Special Report to the public. OLMA Media Mentions By Week OLMA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OLMA News Sentiment▼0.640.58▲Average Medical News Sentiment OLMA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OLMA Articles This Week▼192▲OLMA Articles Average Week Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GHRS News STOK News CALT News ZYME News PHAR News LYEL News ORIC News PHAT News SLN News CVAC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OLMA) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCollapse of the Petrodollar Colonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
